Eliem Therapeutics (ELYM) Competitors $1.30 -0.04 (-2.99%) As of 04/24/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ELYM vs. TNGX, ACIU, DERM, FATE, FDMT, PBYI, TARA, IKT, PRQR, and TLSAShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Tango Therapeutics (TNGX), AC Immune (ACIU), Journey Medical (DERM), Fate Therapeutics (FATE), 4D Molecular Therapeutics (FDMT), Puma Biotechnology (PBYI), Protara Therapeutics (TARA), Inhibikase Therapeutics (IKT), ProQR Therapeutics (PRQR), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry. Eliem Therapeutics vs. Tango Therapeutics AC Immune Journey Medical Fate Therapeutics 4D Molecular Therapeutics Puma Biotechnology Protara Therapeutics Inhibikase Therapeutics ProQR Therapeutics Tiziana Life Sciences Tango Therapeutics (NASDAQ:TNGX) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk. Does the MarketBeat Community prefer TNGX or ELYM? Tango Therapeutics received 20 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 74.36% of users gave Tango Therapeutics an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote. CompanyUnderperformOutperformTango TherapeuticsOutperform Votes2974.36% Underperform Votes1025.64% Eliem TherapeuticsOutperform Votes956.25% Underperform Votes743.75% Do insiders and institutionals have more ownership in TNGX or ELYM? 79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 6.3% of Tango Therapeutics shares are held by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer TNGX or ELYM? Tango Therapeutics presently has a consensus price target of $12.33, suggesting a potential upside of 744.75%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Tango Therapeutics is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is TNGX or ELYM more profitable? Eliem Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -284.42%. Eliem Therapeutics' return on equity of -47.03% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tango Therapeutics-284.42% -49.64% -32.00% Eliem Therapeutics N/A -47.03%-45.97% Which has better earnings and valuation, TNGX or ELYM? Eliem Therapeutics has lower revenue, but higher earnings than Tango Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTango Therapeutics$42.07M3.75-$101.74M-$1.21-1.21Eliem TherapeuticsN/AN/A-$35.12M-$0.53-2.45 Which has more volatility and risk, TNGX or ELYM? Tango Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the S&P 500. Does the media favor TNGX or ELYM? In the previous week, Tango Therapeutics had 4 more articles in the media than Eliem Therapeutics. MarketBeat recorded 4 mentions for Tango Therapeutics and 0 mentions for Eliem Therapeutics. Tango Therapeutics' average media sentiment score of 1.38 beat Eliem Therapeutics' score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Tango Therapeutics Positive Eliem Therapeutics Neutral SummaryTango Therapeutics beats Eliem Therapeutics on 13 of the 17 factors compared between the two stocks. Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.68M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.30%P/E Ratio-2.457.1422.1418.40Price / SalesN/A238.89389.70101.29Price / CashN/A65.6738.2034.62Price / Book0.336.266.664.18Net Income-$35.12M$142.48M$3.21B$247.71M7 Day Performance3.17%7.90%6.16%6.56%1 Month Performance-1.52%-4.23%-2.86%-2.25%1 Year Performance-67.34%-2.70%16.43%4.67% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$1.30-3.0%N/A-61.7%$38.68MN/A-2.459TNGXTango Therapeutics2.162 of 5 stars$1.38+7.0%$12.33+793.7%-80.1%$149.19M$42.07M-1.1790ACIUAC Immune2.4254 of 5 stars$1.48flat$12.00+710.8%-28.4%$148.61M$27.31M-3.22140Positive NewsDERMJourney Medical2.7529 of 5 stars$6.33+1.3%$9.88+56.0%+113.4%$146.25M$56.13M-6.7390FATEFate Therapeutics3.7983 of 5 stars$1.25+12.6%$5.43+334.3%-66.9%$143.26M$13.63M-0.76550Positive NewsGap DownHigh Trading VolumeFDMT4D Molecular Therapeutics2.629 of 5 stars$3.08+0.7%$26.71+767.3%-85.8%$142.61M$37,000.00-1.08120Analyst ForecastNews CoveragePBYIPuma Biotechnology3.5338 of 5 stars$2.86flat$7.00+144.8%-38.5%$141.89M$230.47M5.96200Analyst UpgradeNews CoverageTARAProtara Therapeutics1.7197 of 5 stars$3.85-1.3%$20.40+429.9%+41.6%$141.55MN/A-1.3730Upcoming EarningsIKTInhibikase Therapeutics0.9321 of 5 stars$1.89-0.5%$6.50+243.9%+13.4%$140.51M$260,000.00-0.716PRQRProQR Therapeutics2.4186 of 5 stars$1.32+15.8%$9.50+619.7%-27.0%$138.88M$18.91M-4.13180News CoverageGap UpTLSATiziana Life Sciences1.0185 of 5 stars$1.13+5.6%N/A+60.0%$132.04MN/A0.008Positive News Related Companies and Tools Related Companies Tango Therapeutics Alternatives AC Immune Alternatives Journey Medical Alternatives Fate Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Puma Biotechnology Alternatives Protara Therapeutics Alternatives Inhibikase Therapeutics Alternatives ProQR Therapeutics Alternatives Tiziana Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELYM) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELYM Stock Free ELYM Stock Alerts